Literature DB >> 10873752

Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.

W Olszewska1, O E Obeid, M W Steward.   

Abstract

Synthetic peptides mimicking a conformational B-cell epitope (M2) of the measles virus fusion protein (MVF) were used for the immunization of BALB/c mice and the anti-peptide and anti-virus antibody titers induced were compared. Of the panel of tested peptides, a chimeric peptide consisting of two copies of a T-helper epitope (residues 288-302 of MVF) and one copy of the mimotope M2 (TTM2) and a multiple antigen peptide with eight copies of M2 (MAP-M2) induced the highest titers of anti-M2 and anti-MV antibodies. Furthermore, peptides TTM2 and MAP-M2 induced antibodies with highest affinity for the mimotope and highest avidity for measles virus. Immunization with the MAP-M2 construct induced high titers of high-affinity anti-M2 antibody despite the absence of a T-helper epitope, and lymphocyte proliferation data suggest that the addition of M2 to the MAP resulted in the generation of a structure capable of stimulating T-cell help. Sera with anti-M2 reactivity were pooled according to affinity values for binding to M2, and high- and low-affinity pools were tested for their ability to prevent MV-induced encephalitis in a mouse model. The high-affinity serum pool conferred protection in 100% of mice, whereas the lower affinity pool conferred protection to only 50% of animals. These results indicate the potential of mimotopes for use as synthetic peptide immunogens and highlight the importance of designing vaccines to induce antibodies of high affinity. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873752     DOI: 10.1006/viro.2000.0285

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  No evidence of abnormal regulation of antibody response to coxsackievirus B4 antigen in prediabetic children.

Authors:  L Heino; M Lönnrot; M Knip; A Kupila; S Erkkilä; A Toivonen; P Vähäsalo; J Ilonen; O Simell; H Hyöty
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

3.  HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection.

Authors:  Nitya Nair; William J Moss; Susana Scott; Nanthalile Mugala; Zaza M Ndhlovu; Kareem Lilo; Judith J Ryon; Mwaka Monze; Thomas C Quinn; Simon Cousens; Felicity Cutts; Diane E Griffin
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

Review 4.  Mimotope vaccination--from allergy to cancer.

Authors:  Regina Knittelfelder; Angelika B Riemer; Erika Jensen-Jarolim
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

5.  Anti-ids in allergy: timeliness of a classic concept.

Authors:  Julia Wallmann; Isabella Pali-Schöll; Erika Jensen-Jarolim
Journal:  World Allergy Organ J       Date:  2010-06       Impact factor: 4.084

6.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

7.  High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria.

Authors:  Yeung Lo Tutterrow; Ali Salanti; Marion Avril; Joseph D Smith; Ian S Pagano; Simon Ako; Josephine Fogako; Rose G F Leke; Diane Wallace Taylor
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

8.  Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.

Authors:  Erin Crossey; Kathryn Frietze; David L Narum; David S Peabody; Bryce Chackerian
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants.

Authors:  W Olszewska; C D Partidos; M W Steward
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

10.  Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome.

Authors:  Chun-Yu Lin; Chun-Ching Chiu; Ju Cheng; Chia-Yun Lin; Ya-Fang Shi; Chun-Chou Tsai; Bor-Show Tzang; Tsai-Ching Hsu
Journal:  Virulence       Date:  2017-11-30       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.